Please use this identifier to cite or link to this item: http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/3460
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAltay, D. U.-
dc.contributor.authorKorkmaz, M.-
dc.contributor.authorErgun, S.-
dc.contributor.authorKorkmaz, H.-
dc.contributor.authorNoyan, T.-
dc.date.accessioned2023-01-06T11:05:47Z-
dc.date.available2023-01-06T11:05:47Z-
dc.date.issued2021-
dc.identifier.citationAltay, DU., Korkmaz, M., Ergun, S., Korkmaz, H., Noyan, T. (2021). Salivary irisin: potential inflammatory biomarker in recurrent apthous stomatitis patients. European Review For Medical and Pharmacological Sciences, 25(5), 2252-2259.Doi:10.26355/eurrev_202103_25257en_US
dc.identifier.isbn1128-3602-
dc.identifier.urihttp://dx.doi.org/10.26355/eurrev_202103_25257-
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000627906600021-
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/33755963-
dc.identifier.urihttp://earsiv.odu.edu.tr:8080/xmlui/handle/11489/3460-
dc.descriptionWoS Categories : Pharmacology & Pharmacy Web of Science Index : Science Citation Index Expanded (SCI-EXPANDED) Research Areas : Pharmacology & Pharmacyen_US
dc.description.abstractOBJECTIVE: Recurrent Aphthous Stomatitis (RAS) is the most common inflammatory condition of the oral mucosa characterised by recurrent onset of single or multiple painful ulcers mainly affecting the nonkeratinized oral mucosa. RAS mostly occurs in healthy individuals with no associated systemic diseases. Irisin is a newly identified adipomyokine and research has revealed that it has anti-inflammatory effects. The aim of this study was to investigate the significance of salivary irisin levels in patients with recurrent apthous stomatitis (RAS). PATIENTS AND METHODS: In this investigation, 80 individuals were evaluated. The patient group included 30 patients diagnosed with RAS and each control group consisted of 25 smoker and non-smoker healthy individuals. Saliva samples were collected and salivary irisin, interleukin-2 (IL-2) and interferon-gamma (IF-gamma) levels were determined using enzyme-linked immunosorbent assay (ELISA). RESULTS: IL-2 and IF-gamma levels in RAS patients were significantly higher than control smoker and non-smoker groups (p=0.0001, p=0.0001, respectively). Irisin level was higher in RAS patients than smoker controls and non-smoker controls. The level of irisin was found as sensitive and specific as IL-2 and more sensitive and specific than IF-gamma. The salivary levels of pro-inflammatory cytokines IL-2, IF-gamma and irisin were higher in RAS group compared to controls. CONCLUSIONS: This is the first report evaluating the irisin an adipo-myokine as an inflammatory biomarker in RAS.en_US
dc.description.sponsorshipFunding Orgs : Ordu University Scientific Research Foundation [A-1813]; Ordu University BAP Unit Funding Name Preferred : Ordu University Scientific Research Foundation(Ordu University); Ordu University BAP Unit Funding Text : This investigation was funded by Ordu University Scientific Research Foundation with the project number A-1813. Thanks to the Ordu University BAP Unit for their support..en_US
dc.language.isoengen_US
dc.publisherVERDUCI PUBLISHER ROMEen_US
dc.relation.isversionof10.26355/eurrev_202103_25257en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAPHTHOUS STOMATITIS; ADIPOSE-TISSUE; EXPRESSION; DEFICIENCIES; ASSOCIATION; INHIBITION; SMOKING; MUCOSA; CELLS; SERUMen_US
dc.subjectInflammation; Irisin; RASen_US
dc.titleSalivary irisin: potential inflammatory biomarker in recurrent apthous stomatitis patientsen_US
dc.typearticleen_US
dc.relation.journalEUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCESen_US
dc.contributor.departmentOrdu Üniversitesien_US
dc.contributor.authorID0000-0002-7733-0177en_US
dc.identifier.volume25en_US
dc.identifier.issue5en_US
dc.identifier.startpage2252en_US
dc.identifier.endpage2259en_US
Appears in Collections:Beslenme ve Diyetetik

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.